Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization

‘Small Changes' to Diet and Physical Activity Behaviors for Weight Management

Hills, A. P., Byrne, N. M., Lindstrom, R. C., & Hill, J. O. (2013) · Obesity Facts · doi:10.1159/000345030 · Cited by 9,526 · see citing works

Inflammation and metabolic disorders

Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199 · see citing works

Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance

Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518 · see citing works

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance

Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760 · see citing works

Macrophage plasticity and polarization: in vivo veritas

Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · see citing works

Alternative activation of macrophages

Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189 · see citing works

Obesity induces a phenotypic switch in adipose tissue macrophage polarization

Lumeng, C. N., Bodzin, J. L., & Saltiel, A. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29881 · Cited by 4,664 · see citing works

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837 · see citing works

Obesity

Haslam, D. W., & James, W. P. T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67483-1 · Cited by 3,757 · see citing works

Inflammatory Mechanisms in Obesity

Gregor, M. F., & Hotamisligil, G. S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101322 · Cited by 3,754 · see citing works

Macrophages, inflammation, and insulin resistance

Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733 · see citing works

PRDM16 controls a brown fat/skeletal muscle switch

Seale, P., Bjork, B., Yang, W., Kajimura, S., Chin, S., Kuang, S., Scimè, A., Devarakonda, S., Conroe, H. M., Erdjument-Bromage, H., et al. (2008) · Nature · doi:10.1038/nature07182 · Cited by 2,347 · cited 1× · see citing works

Protection from obesity-induced insulin resistance in mice lacking TNF-α function

Uysal, K. T., Wiesbrock, S. M., Marino, M. W., & Hotamisligil, G. S. (1997) · Nature · doi:10.1038/39335 · Cited by 2,234 · see citing works

Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters

Feuerer, M., Herrero, L., Cipolletta, D., Naaz, A., Wong, J., Nayer, A., Lee, J., Goldfine, A. B., Benoist, C., Shoelson, S., et al. (2009) · Nature Medicine · doi:10.1038/nm.2002 · Cited by 2,145 · see citing works

FGF-21 as a novel metabolic regulator

Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125 · see citing works

Towards a molecular understanding of adaptive thermogenesis

Lowell, B. B., & Spiegelman, B. M. (2000) · Nature · doi:10.1038/35007527 · Cited by 1,630 · see citing works

Endocrine Regulation of the Fasting Response by PPARα-Mediated Induction of Fibroblast Growth Factor 21

Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504 · see citing works

Hepatic Fibroblast Growth Factor 21 Is Regulated by PPARα and Is a Key Mediator of Hepatic Lipid Metabolism in Ketotic States

Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495 · see citing works

FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis

Fisher, F. M., Kleiner, S., Douris, N., Fox, E. C., Mepani, R. J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J. S., Maratos-Flier, E., et al. (2012) · Genes & Development · doi:10.1101/gad.177857.111 · Cited by 1,478 · see citing works

Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis

Nguyen, K. D., Qiu, Y., Cui, X., Goh, Y. P. S., Mwangi, J., David, T., Mukundan, L., Brombacher, F., Locksley, R. M., & Chawla, A. (2011) · Nature · doi:10.1038/nature10653 · Cited by 1,038 · see citing works

Macrophage polarization: an opportunity for improved outcomes in biomaterials and regenerative medicine

Brown, B. N., Ratner, B. D., Goodman, S. B., Amar, S., & Badylak, S. F. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.02.034 · Cited by 926 · cited 1× · see citing works

Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages

Molofsky, A. B., Nussbaum, J. C., Liang, H.-E., Dyken, S. J. V., Cheng, L. E., Mohapatra, A., Chawla, A., & Locksley, R. M. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20121964 · Cited by 879 · see citing works

Ablation of PRDM16 and Beige Adipose Causes Metabolic Dysfunction and a Subcutaneous to Visceral Fat Switch

Cohen, P., Levy, J. D., Zhang, Y., Frontini, A., Kolodin, D., Svensson, K. J., Lo, J. C., Zeng, X., Ye, L., Khandekar, M. J., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.021 · Cited by 878 · see citing works

Eosinophils and Type 2 Cytokine Signaling in Macrophages Orchestrate Development of Functional Beige Fat

Qiu, Y., Nguyen, K. D., Odegaard, J. I., Cui, X., Tian, X., Locksley, R. M., Palmiter, R. D., & Chawla, A. (2014) · Cell · doi:10.1016/j.cell.2014.03.066 · Cited by 869 · see citing works

Adaptive thermogenesis in adipocytes: Is beige the new brown?

Wu, J., Cohen, P., & Spiegelman, B. M. (2013) · Genes & Development · doi:10.1101/gad.211649.112 · Cited by 828 · see citing works

Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes

Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T. R., & Muscelli, E. (2016) · Diabetes · doi:10.2337/db15-1356 · Cited by 713 · see citing works

Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608 · see citing works

Beyond stem cells: self-renewal of differentiated macrophages

Sieweke, M. H., & Allen, J. E. (2013) · Science · doi:10.1126/science.1242974 · Cited by 503 · see citing works

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

Xu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Mayoux, E., Kaneko, S., & Ota, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.028 · Cited by 497 · see citing works

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

Roden, M., Weng, J., Eilbracht, J., Delafont, B., Kim, G., Woerle, H. J., & Broedl, U. C. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70084-6 · Cited by 451 · see citing works

Macrophage Plasticity and Polarization in Liver Homeostasis and Pathology

Sica, A., Invernizzi, P., & Mantovani, A. (2014) · Hepatology · doi:10.1002/hep.26754 · Cited by 422 · see citing works

Crosstalk between Adipocytes and Immune Cells in Adipose Tissue Inflammation and Metabolic Dysregulation in Obesity

Huh, J. Y., Park, Y. J., Ham, M., & Kim, J. B. (2014) · Molecules and Cells · doi:10.14348/molcells.2014.0074 · Cited by 416 · see citing works

The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels

Hawley, S. A., Ford, R. J., Smith, B. K., Gowans, G. J., Mancini, S. J., Pitt, R. D., Day, E. A., Salt, I. P., Steinberg, G. R., & Hardie, D. G. (2016) · Diabetes · doi:10.2337/db16-0058 · Cited by 398 · see citing works

Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus

Vallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K. A., Koepsell, H., Cunard, R., Sharma, K., Thomson, S. C., & Rieg, T. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00409.2012 · Cited by 370 · see citing works

Adiponectin Enhances Cold-Induced Browning of Subcutaneous Adipose Tissue via Promoting M2 Macrophage Proliferation

Hui, X. H., Gu, P., Zhang, J., Nie, T., Pan, Y., Wu, D., Feng, T., Zhong, C., Wang, Y., Lam, K. S. L., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.004 · Cited by 349 · see citing works

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

Nauck, M. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s50773 · Cited by 343 · see citing works

Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice

Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., Eguchi, J., Horiguchi, C. S., Nishii, N., Yamada, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100777 · Cited by 341 · see citing works

Familial Renal Glucosuria and SGLT2

Santer, R., & Calado, J. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04010609 · Cited by 341 · see citing works

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.05.014 · Cited by 312 · see citing works

CCR5 Plays a Critical Role in Obesity-Induced Adipose Tissue Inflammation and Insulin Resistance by Regulating Both Macrophage Recruitment and M1/M2 Status

Kitade, H., Sawamoto, K., Nagashimada, M., Inoue, H., Yamamoto, Y., Sai, Y., Takamura, T., Yamamoto, H., Miyamoto, K., Ginsberg, H. N., et al. (2012) · Diabetes · doi:10.2337/db11-1506 · Cited by 292 · see citing works

Macrophage Polarization in Obesity and Type 2 Diabetes: Weighing Down Our Understanding of Macrophage Function?

Kraakman, M. J., Murphy, A. J., Jandeleit-Dahm, K. A. M., & Kammoun, H. L. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00470 · Cited by 278 · see citing works

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor

Scheen, A. J. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0126-x · Cited by 237 · see citing works

Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)

van den Heuvel, L. P., Assink, K., Willemsen, M. A. A. P., & Monnens, L. A. H. (2002) · Human Genetics · doi:10.1007/s00439-002-0820-5 · Cited by 220 · see citing works

Turning WAT into BAT: a review on regulators controlling the browning of white adipocytes

Lo, K. A., & Sun, L. (2013) · Bioscience Reports · doi:10.1042/bsr20130046 · Cited by 214 · see citing works

Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet‐Induced Obese (DIO) Rats

Devenny, J. J., Godonis, H. E., Harvey, S. J., Rooney, S., Cullen, M. J., & Pelleymounter, M. A. (2012) · Obesity · doi:10.1038/oby.2012.59 · Cited by 212 · see citing works

Roles of Chemokines and Chemokine Receptors in Obesity-Associated Insulin Resistance and Nonalcoholic Fatty Liver Disease

Xu, L., Kitade, H., Ni, Y., & Ota, T. (2015) · Biomolecules · doi:10.3390/biom5031563 · Cited by 185 · see citing works

A P hase IIb , randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

Ferrannini, E., SEMAN, L. J., Seewaldt-Becker, E., Hantel, S., Pinnetti, S., & Woerle, H. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12081 · Cited by 181 · see citing works

Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice

Obata, A., Kubota, N., Kubota, T., Iwamoto, M., Satō, H., Sakurai, Y., Takamoto, I., Katsuyama, H., Suzuki, Y., Fukazawa, M., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1588 · Cited by 143 · see citing works

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects

SEMAN, L. J., Macha, S., Nehmiz, G., Simons, G., Ren, B., Pinnetti, S., Woerle, H. J., & Dugi, K. A. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.16 · Cited by 136 · see citing works

Ontogeny and Polarization of Macrophages in Inflammation: Blood Monocytes Versus Tissue Macrophages

Dey, A., Allen, J., & Hankey-Giblin, P. A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00683 · Cited by 126 · see citing works

Differential Effects of Leptin and Adiponectin in Endothelial Angiogenesis

Adya, R., Tan, B. K., & Randeva, H. S. (2015) · Journal of Diabetes Research · doi:10.1155/2015/648239 · Cited by 126 · see citing works

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes

Polidori, D., Mari, A., & Ferrannini, E. (2014) · Diabetologia · doi:10.1007/s00125-014-3196-x · Cited by 114 · see citing works

Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism

Briand, F., Mayoux, E., Brousseau, E., Burr, N., Urbain, I., Costard, C., Mark, M., & Sulpice, T. (2016) · Diabetes · doi:10.2337/db16-0049 · Cited by 114 · see citing works

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

Qiang, S., Nakatsu, Y., Seno, Y., Fujishiro, M., Sakoda, H., Kushiyama, A., Mori, K., Matsunaga, Y., Yamamotoya, T., Kamata, H., et al. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0102-8 · Cited by 113 · see citing works

Sodium Intake Regulates Glucose Homeostasis through the PPARδ/Adiponectin-Mediated SGLT2 Pathway

Zhao, Y., Gao, P., Sun, F., Li, Q., Chen, J., Yu, H., Li, L., Wei, X., He, H., Lu, Z., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.019 · Cited by 97 · see citing works

Liver innate immune cells and insulin resistance: the multiple facets of Kupffer cells

Jager, J., Aparicio‐Vergara, M., & Aouadi, M. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12483 · Cited by 90 · see citing works

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects

Sarashina, A., Koiwai, K., SEMAN, L. J., Yamamura, N., Taniguchi, A., Negishi, T., Sesoko, S., Woerle, H. J., & Dugi, K. A. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rg-082 · Cited by 86 · see citing works

Association of physical activity with all-cause mortality and incident and prevalent cardiovascular disease among patients with type 1 diabetes: the EURODIAB Prospective Complications Study

Tielemans, S. M. A. J., Soedamah‐Muthu, S. S., Neve, M. D., Toeller, M., Chaturvedi, N., Fuller, J., & Stamatakis, E. A. (2012) · Diabetologia · doi:10.1007/s00125-012-2743-6 · Cited by 84 · see citing works

Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice

Nakano, S., Katsuno, K., Isaji, M., Nagasawa, T., Buehrer, B. M., Walker, S., Wilkison, W. O., & Cheatham, B. (2015) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2015.02.005 · Cited by 82 · see citing works

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents

Vivian, E. (2014) · Drugs in Context · doi:10.7573/dic.212264 · Cited by 68 · see citing works

Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

White, J. R. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015573564 · Cited by 37 · see citing works

The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors

Cangoz, S., Chang, Y.-Y., Chempakaseril, S. J., Guduru, R. C., Huynh, L. M., John, J. S., John, S. T., Joseph, M. E., Judge, R., Kimmey, R., et al. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12077 · Cited by 35 · see citing works

Tofogliflozin: A highly selective SGLT2 inhibitor for the treatment of type 2 diabetes

Rosenwasser, R., Rosenwasser, J. N., Choksi, R. R., & Epstein, B. J. (2014) · Drugs of today · doi:10.1358/dot.2014.50.11.2232267 · Cited by 20 · see citing works

Macrophage polarization: an important role in inflammatory diseases

Luo, M., Zhao, F., Cheng, H., Su, M., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1352946 · Cited by 515 · see citing works

Signaling pathways in obesity: mechanisms and therapeutic interventions

Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 456 · see citing works

Insulin resistance and cardiovascular disease

Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023) · Journal of International Medical Research · doi:10.1177/03000605231164548 · Cited by 413 · see citing works

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 370 · see citing works

The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure

Thomas, M. C., & Cherney, D. Z. I. (2018) · Diabetologia · doi:10.1007/s00125-018-4669-0 · Cited by 351 · see citing works

Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease

Bonnet, F., & Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.09.005 · Cited by 311 · see citing works

Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

Scheen, A. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0392-2 · Cited by 268 · see citing works

Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers

Antoniades, C. A., Tousoulis, D., Vavlukis, M., Fleming, I., Duncker, D. J., Eringa, E. C., Manfrini, O., Antonopoulos, A. S., Oikonomou, E. K., Padró, T., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad484 · Cited by 237 · see citing works

Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms

Lee, P. C., Ganguly, S., & Goh, S. ‐. (2018) · Obesity Reviews · doi:10.1111/obr.12755 · Cited by 189 · see citing works

Role of Leptin in Cardiovascular Diseases

Poetsch, M. S., Strano, A., & Guan, K. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00354 · Cited by 173 · see citing works

Adipose Tissue Inflammation and Cardiovascular Disease: An Update

Rana, M. N., & Neeland, I. J. (2022) · Current Diabetes Reports · doi:10.1007/s11892-021-01446-9 · Cited by 169 · see citing works

Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?

Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169 · see citing works

Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus

Wu, J., Yang, K., Fan, H., Wei, M., & Xiong, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1114424 · Cited by 155 · see citing works

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases

Tsai, K., Chen, Y., Chiou, T. T., Chu, T., Li, L., Ng, H., Lee, W., & Lee, C. (2021) · Antioxidants · doi:10.3390/antiox10081166 · Cited by 135 · see citing works

Sex-based differences in insulin resistance

Gado, M., Tsaousidou, E., Bornstein, S. R., & Perakakis, N. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0245 · Cited by 125 · see citing works

SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)–Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice

Ortega, R., Collado, A., Selles, F., Navarro, H. G., Sanz, M., Real, J. T., & Piqueras, L. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312659 · Cited by 102 · see citing works

Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection

Hou, Y., Zheng, C., Yen, T., & Lu, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217833 · Cited by 108 · see citing works

Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review

Yaribeygi, H., Sathyapalan, T., Maleki, M., Jamialahmadi, T., & Sahebkar, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117090 · Cited by 94 · see citing works

Low-grade inflammation in type 2 diabetes: a cross-sectional study from a Danish diabetes outpatient clinic

Okdahl, T., Wegeberg, A., Pociot, F., Brock, B., Størling, J., & Brock, C. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062188 · Cited by 94 · see citing works

Endothelial Dysfunction in Diabetes

Takeda, Y., Matoba, K., Sekiguchi, K., Nagai, Y., Yokota, T., Utsunomiya, K., & Nishimura, R. (2020) · Biomedicines · doi:10.3390/biomedicines8070182 · Cited by 93 · see citing works

SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease

Moon, J. S., Hong, J. H., Jung, Y. J., Ferrannini, E., Nauck, M. A., & Lim, S. K. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.03.005 · Cited by 75 · see citing works

Obesity and Breast Cancer Risk: The Oncogenic Implications of Metabolic Dysregulation

Naaman, S., Shen, S., Zeytinoglu, M., & Iyengar, N. M. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac241 · Cited by 66 · see citing works

TLR9 Binding to Beclin 1 and Mitochondrial SIRT3 by a Sodium-Glucose Co-Transporter 2 Inhibitor Protects the Heart from Doxorubicin Toxicity

Wang, C., Chen, C., Lin, M.-H., Su, H., Ho, M.-Y., Yeh, J., Tsai, M., Hsieh, C., & Wen, M. (2020) · Biology · doi:10.3390/biology9110369 · Cited by 61 · see citing works

Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice

Bamba, R., Okamura, T., Hashimoto, Y., Majima, S., Senmaru, T., Ushigome, E., Nakanishi, N., Asano, M., Yamazaki, M., Takakuwa, H., et al. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12814 · Cited by 61 · see citing works

SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in Type 2 Diabetes: A Narrative Review

Janež, A., & Fioretto, P. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01104-z · Cited by 59 · see citing works

Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-α, IL-1β, and IL-18 in rat liver

ElMahdy, M. K., Helal, M. G., & Ebrahim, T. M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106730 · Cited by 60 · see citing works

Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus

Zhang, R., Xie, Q., Lu, X., Fan, R., & Tong, N. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01325-9 · Cited by 57 · see citing works

Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules

Hosokawa, K., Takata, T., Sugihara, T., Matono, T., Koda, M., Kanda, T., Taniguchi, S., Ida, A., Mae, Y., Yamamoto, M., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010190 · Cited by 54 · see citing works

Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches

Xu, J., Hirai, T., Koya, D., & Kitada, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010137 · Cited by 53 · see citing works

Macrophage polarization and signaling in diabetic kidney disease: a catalyst for disease progression

Youssef, N., Noureldein, M. H., Riachi, M. E., Haddad, A., & Eid, A. A. (2023) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00266.2023 · Cited by 48 · see citing works

Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes

Yang, Y., Zhao, C., Ye, Y., Yu, M., & Qu, X. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00190 · Cited by 48 · see citing works

Hospitalization for heart failure incidence according to the transition in metabolic health and obesity status: a nationwide population-based study

Lee, Y., Kim, D. H., Kim, S. M., Kim, N. H., Choi, K. M., Baik, S. H., Park, Y. G., Han, K., & Yoo, H. J. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01051-2 · Cited by 44 · see citing works

Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)

Koshizaka, M., Ishikawa, K., Ishibashi, R., Maezawa, Y., Sakamoto, K., Uchida, D., Nakamura, S., Yamaga, M., Yokoh, H., Kobayashi, A., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13750 · Cited by 44 · see citing works

Association between novel Glucose-Lowering drugs and risk of Asthma: A network Meta-Analysis of cardiorenal outcome trials

Wang, A., Tang, H., Zhang, N., & Feng, X. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109080 · Cited by 42 · see citing works

Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved

Afşar, B., & Afşar, R. E. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.10.004 · Cited by 38 · see citing works

The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials

Gohari, S., Ismail‐Beigi, F., Mahjani, M., Ghobadi, S., Jafari, A., Ahangar, H., & Gohari, S. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01512-1 · Cited by 39 · see citing works

Anti-inflammation and anti-oxidation: the key to unlocking the cardiovascular potential of SGLT2 Inhibitors and GLP1 receptor agonists

Myasoedova, V. A., Bozzi, M., Valerio, V., Moschetta, D., Massaiu, I., Rusconi, V., Di Napoli, D., Ciccarelli, M., Parisi, V., Agostoni, P., et al. (2023) · Antioxidants · doi:10.3390/antiox13010016 · Cited by 35 · see citing works

Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease

Ma, Y., Zhang, G., Kuang, Z., Xu, Q., Ye, T., Li, X., Qu, N., Han, F., Kan, C., & Sun, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944886 · Cited by 35 · see citing works

Empagliflozin Induces White Adipocyte Browning and Modulates Mitochondrial Dynamics in KK Cg-Ay/J Mice and Mouse Adipocytes

Xu, L., Xu, C., Liu, X., Li, X., Li, T., Yu, X., Xue, M., Yang, J., Kosmas, C. E., Moris, D., et al. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.745058 · Cited by 34 · see citing works

Adipokines and Cardiometabolic Heart Failure with Preserved Ejection Fraction: A State-of-the-Art Review

Theodorakis, N., Kreouzi, M., Hitas, C., Anagnostou, D., & Nikolaou, M. (2024) · Diagnostics · doi:10.3390/diagnostics14232677 · Cited by 32 · see citing works

Obesity-related asthma and its relationship with microbiota

Huang, J., Zhou, X., Dong, B., Tan, H., Li, Q., Zhang, J., Su, H., & Sun, X. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1303899 · Cited by 31 · see citing works

Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review

Xie, L., & Wenfang, X. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120543 · Cited by 33 · see citing works

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy

Złotek, M., Kurowska, A., Herbet, M., & Piątkowska‐Chmiel, I. (2023) · Biomedicines · doi:10.3390/biomedicines11113035 · Cited by 30 · see citing works

Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin

Zeng, Y.-H., Liu, S.-C., Lee, C., Sun, F., & Liu, J. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-21486-9 · Cited by 29 · see citing works

Eccentric exercise and dietary restriction inhibits M1 macrophage polarization activated by high-fat diet-induced obesity

Luo, W., Ai, L., Wang, B., Wang, L., Gan, Y., Liu, C., Jensen, J., & Zhou, Y. (2020) · Life Sciences · doi:10.1016/j.lfs.2019.117246 · Cited by 28 · see citing works

Epicardial Adipose Tissue in Myocardial Disease: From Physiology to Heart Failure Phenotypes

Antonopoulos, A. S., Papastamos, C., Cokkinos, D. V., Tsioufis, K. P., & Tousoulis, D. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101841 · Cited by 27 · see citing works

Role and mechanism of specialized pro-resolving mediators in obesity-associated insulin resistance

Liu, X., Tang, Y., Luo, Y., Gao, Y., & He, L. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02207-9 · Cited by 27 · see citing works

The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials

Liu, X., Chen, Y., Liu, T., Cai, L., Yang, X., & Mou, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1115321 · Cited by 27 · see citing works

SGLT2 Inhibitors in Cancer Patients: A Comprehensive Review of Clinical, Biochemical, and Therapeutic Implications in Cardio-Oncology

Greco, A., Canale, M. L., Quagliariello, V., Oliva, S., Tedeschi, A., Inno, A., Biasio, M. D., Bisceglia, I., Tarantini, L., Maurea, N., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104780 · Cited by 26 · see citing works

Obesity and endometrial cancer: biological mechanisms, nutritional strategies, and clinical perspectives

Simancas‐Racines, D., Campuzano-Donoso, M., Román-Galeano, N. M., Zambrano-Villacres, R., Memoli, P., Verde, L., Reytor-González, C., & Carbone, L. (2025) · Food and Agricultural Immunology · doi:10.1080/09540105.2025.2510961 · Cited by 29 · see citing works

SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?

Scheen, A. J. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.06.003 · Cited by 26 · see citing works

Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes

Hashikata, T., Ikutomi, M., Jimba, T., Shindo, A., Kakuda, N., Katsushika, S., Yokoyama, M., Kishi, M., Sato, T., Matsushita, M., et al. (2020) · Heart and Vessels · doi:10.1007/s00380-020-01621-0 · Cited by 23 · see citing works

Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history

Avogaro, A., de Kreutzenberg, S. V., Morieri, M. L., Fadini, G. P., & Prato, S. D. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00247-9 · Cited by 21 · see citing works

Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy

Bardaweel, S. K., & Issa, A. (2022) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps32879 · Cited by 21 · see citing works

SGLT-2 inhibitors in obesity and its associated cardiometabolic disorders: where do we stand?

Vallianou, N. G., Tsilingiris, D., Kounatidis, D. C., Lempesis, I. G., Karampela, Ι., & Dalamaga, Μ. (2022) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16342 · Cited by 21 · see citing works

Sodium-Glucose Cotransporter 2 Inhibitors Improve Body Composition by Increasing the Skeletal Muscle Mass/Fat Mass Ratio in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study

Volpe, S., Vozza, A., Lisco, G., Fanelli, M., Racaniello, D., Bergamasco, A., Triggiani, D., Pierangeli, G., Pergola, G. D., Tortorella, C., et al. (2024) · Nutrients · doi:10.3390/nu16223841 · Cited by 20 · see citing works

Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action

Kochanowska, A., Rusztyn, P., Szczerkowska, K., Surma, S., Gąsecka, A., Jaguszewski, M. J., Szarpak, Ł., & Filipiak, K. J. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10070268 · Cited by 20 · see citing works

Therapeutic strategies targeting mechanisms of macrophages in diabetic heart disease

Zhang, C., Shi, Y., Liu, C., Sudesh, S. M., Zhao, H., Li, P., Liu, Q., Ma, Y., Shi, A., & Cai, H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02273-4 · Cited by 22 · see citing works

The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy

Chen, H., Teng, D., Xu, B., Wang, C., Wang, H., Jia, W., Gong, L., Dong, H., Zhong, L., & Yang, J. (2023) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-023-10390-w · Cited by 19 · see citing works

Artificially induced in situ macrophage polarization: An emerging cellular therapy for immuno-inflammatory diseases

Chatterjee, O., & Sur, D. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176006 · Cited by 19 · see citing works

Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension

Hojná, S., Rauchová, H., Malínská, H., Marková, I., Hüttl, M., Papoušek, F., Behuliak, M., Miklánková, D., Vaňourková, Z., Neckář, J., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112246 · Cited by 19 · see citing works

SGLT2 Inhibitors and the Mechanisms Involved in Weight Loss

Feder, D., Gouveia, M. R. D. F. V., Govato, T. C. P., & Nassis, C. D. Z. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00236-3 · Cited by 18 · see citing works

Meta-Inflammation and New Anti-Diabetic Drugs: A New Chance to Knock Down Residual Cardiovascular Risk

d’Aiello, A., Bonanni, A., Vinci, R., Pedicino, D., Severino, A., Vita, A. D., Filomia, S., Brecciaroli, M., & Liuzzo, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108643 · Cited by 17 · see citing works

PPARs/macrophages: A bridge between the inflammatory response and lipid metabolism in autoimmune diseases

Wang, Z., Wang, M., Xu, X., Liu, Y., Chen, Q., Wu, B., & Zhang, Y. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149128 · Cited by 17 · see citing works

Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice

Kurtz, R., Libby, A. E., Jones, B. A., Myakala, K., Wang, X., Lee, Y., Knoer, G., Cascio, J. N. L., McCormack, M., Nguyen, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105675 · Cited by 17 · see citing works

Protection of diabetes in aortic abdominal aneurysm: Are antidiabetics the real effectors?

Picatoste, B., Cerro-Pardo, I., Blanco‐Colio, L. M., & Martı́n-Ventura, J. L. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1112430 · Cited by 16 · see citing works

SGLT2 inhibitors in peritoneal dialysis: a promising frontier toward improved patient outcomes

Stepanova, N. (2024) · Renal Replacement Therapy · doi:10.1186/s41100-024-00523-5 · Cited by 17 · see citing works

Managing diabetes in diabetic patients with COVID: where do we start from?

Avogaro, A., Bonora, B. M., & Fadini, G. P. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01739-1 · Cited by 16 · see citing works

Metformin, Empagliflozin, and Their Combination Modulate Ex-Vivo Macrophage Inflammatory Gene Expression

Arefin, A., & Gage, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054785 · Cited by 15 · see citing works

Effect of high-fat diet and empagliflozin on cardiac proteins in mice

Pan, X., Chen, S., Chen, X., Ren, Q., Yue, L., Niu, S., Li, Z., Zhu, R., Chen, X., Jia, Z., et al. (2022) · Nutrition & Metabolism · doi:10.1186/s12986-022-00705-0 · Cited by 15 · see citing works

The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance

Dong, M., Chen, H., Wen, S., Yuan, Y., Yang, L.-L., Li, Y.-Y., Yuan, X.-L., Xu, D.-X., & Zhou, L.-G. (2023) · Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy · doi:10.2147/dmso.s399367 · Cited by 11 · see citing works

Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes

Schnell, O., Valensi, P. E., Standl, E., & Ceriello, A. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.129 · Cited by 14 · see citing works

The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes

Gillard, P., Schnell, O., & Groop, P. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108462 · Cited by 14 · see citing works

Mechanical activation of adipose tissue macrophages mediated by Piezo1 protects against diet-induced obesity by regulating sympathetic activity

Leng, S., Zhang, X., Zhao, R., Jiang, N., Liu, X., Li, X., Feng, Q., Sheng, Z., Wang, S., Peng, J., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156262 · Cited by 13 · see citing works

From Diabetes Care to Heart Failure Management: A Potential Therapeutic Approach Combining SGLT2 Inhibitors and Plant Extracts

Gliozzi, M., Macrì, R., Coppoletta, A. R., Musolino, V., Carresi, C., Scicchitano, M., Bosco, F., Guarnieri, L., Cardamone, A., Ruga, S., et al. (2022) · Nutrients · doi:10.3390/nu14183737 · Cited by 13 · see citing works

Hepatoprotective Effect of SGLT2 Inhibitor on Nonalcoholic Fatty Liver Disease

Sumida, Y., Yoneda, M., Tokushige, K., Kawanaka, M., Fujii, H., Yoneda, M., Imajo, K., Takahashi, H., Ono, M., Nozaki, Y., et al. (2020) · doi:10.36502/2020/droa.6159 · Cited by 12 · see citing works

Molecular crosstalk in perivascular adipose tissue: mechanisms of inflammation, metabolic dysregulation, and therapeutic opportunities in cardiovascular disease

Zhang, S., Jiang, J., Luo, Y., Liu, G., Hu, S., Wan, S., Luo, C., Li, H., Li, N., Vasconcelos, J. D. G. E. S., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1613900 · Cited by 11 · see citing works

Implications of SGLT Inhibition on Redox Signalling in Atrial Fibrillation

Bode, D., Semmler, L., Oeing, C. U., Alogna, A., Schiattarella, G. G., Pieske, B. M., Heinzel, F. R., & Hohendanner, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115937 · Cited by 11 · see citing works

Pleiotropic Effects of SGLT2 Inhibitors: A Focus on Macrophage-Mediated Action.

Shu, B., Chen, X.-S., Liu, Z., Tang, H., Yang, B., & Fu, C.-X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108046 · Cited by 14 · see citing works

SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis

Zhang, Q., Deng, Z., Li, T., Chen, K., & Zeng, Z. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1280547 · Cited by 10 · see citing works

Sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase IV inhibitors and risk of dementia among patients with type 2 diabetes and comorbid mental disorders: A population-based cohort study

Hong, B., Lee, H., Choi, A., Kim, W. J., Cho, Y. M., Yon, D. K., & Shin, J. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101581 · Cited by 10 · see citing works

Metabolite transporters as regulators of macrophage polarization

Cheng, J., Cai, W., Zong, S.-Y., Yu, Y., & Wei, F. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-021-02173-4 · Cited by 10 · see citing works

Influence of modern antidiabetic therapy on body weight in patients with type 2 diabetes mellitus

Салухов, В. В., Ilyinskaya, Т. A., & Minakov, A. A. (2022) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2022-11-1-39-52 · Cited by 12 · see citing works

Bioactive Compounds and Adipocyte Browning Phenomenon

Manríquez-Núñez, J., & Ramos‐Gómez, M. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44070210 · Cited by 10 · see citing works

Efficacy of Hypoglycemic Agents in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A Systematic Review and Network Meta‐Analysis

Ren, Q., Tan, Y., Zhang, G., Dai, Y., Yang, L., Wu, Y., He, H., & Chen, J. (2025) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70021 · Cited by 9 · see citing works

Anti-Inflammatory and Anti-Oxidative Effects of GLP1-RAs and SGLT2i: The Guiding Star Towards Cardiovascular Protection in Type 2 Diabetes

Marcon, L. M. R., & Mazzieri, A. (2025) · Immuno · doi:10.3390/immuno5010011 · Cited by 9 · see citing works

The role of circRNA in insulin resistance and its progression induced by adipose inflammation

Liu, Y., Yue, J., Jiang, Y., Tian, X., & Shu, A. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109042 · Cited by 10 · see citing works

Targeting Renal Proximal Tubule Cells in Obesity-Related Glomerulopathy

Ye, M., Yang, M., Dai, W., Li, H., Zhou, X. C., Chen, Y., & He, L. (2023) · Pharmaceuticals · doi:10.3390/ph16091256 · Cited by 9 · see citing works

Dapagliflozin promotes white adipose tissue browning though regulating angiogenesis in high fat induced obese mice

Xiang, L., Liu, M., Xiang, G., Yue, L., Zhang, J., Xu, X., & Dong, J. (2024) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-024-00747-5 · Cited by 9 · see citing works

Associations of dietary inflammatory potential with postpartum weight change and retention: Results from a cohort study

Qin, Y., Chen, Y., Zhang, Z., Huang, S., Jiao, C., Zhang, Z., & Mao, L. (2021) · Obesity · doi:10.1002/oby.23238 · Cited by 9 · see citing works

Cancer Prevention Effects of Foods, Food Groups, Nutrients, and Their Underlying Mechanisms

Xia, B., Yang, W., Liang, H., Liu, S. Y., Wang, D., & Huang, J. (2022) · ACS Food Science & Technology · doi:10.1021/acsfoodscitech.1c00293 · Cited by 9 · see citing works

The relationship between excess sodium intake and metabolic syndrome: Worth consideration?

Afşar, B., Afşar, R. E., Said, M., Maddukuri, G. S., & Lentine, K. L. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70036 · Cited by 7 · see citing works

The effects of SGLT2 inhibitors in patients with metabolic dysfunction-associated fatty liver disease; a narrative review

Popoviciu, M. S., Păduraru, L., Rahman, M., Supti, F. A., Stoica, R. A., Reurean‐Pintilei, D., Bica, C. I., & Cavalu, S. D. (2024) · Journal of Mind and Medical Sciences · doi:10.22543/2392-7674.1439 · Cited by 5 · see citing works

The cellular and molecular mechanisms mediating the protective effects of sodium–glucose linked transporter 2 inhibitors against metabolic dysfunction‐associated fatty liver disease

Ao, N., Du, J., Jin, S., Suo, L., & Yang, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16043 · Cited by 5 · see citing works

Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?

Nikolic, M. R., Novakovic, J. N., Ramenskaya, G. V., Kokorekin, V. A., Jeremic, N. S., & Jakovljevic, V. L. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00944-4 · Cited by 5 · see citing works

Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study

Çetın, D., Bilgili, E. P., Komaç, Ö., Yetişken, M., & Güney, E. (2025) · Medicina · doi:10.3390/medicina61071152 · Cited by 4 · see citing works

Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome

Kourtidou, C., & Τζιόμαλος, Κ. (2023) · Biomedicines · doi:10.3390/biomedicines11020496 · Cited by 4 · see citing works

Changes in urinary glucose concentration and body weight in patients treated with the selective SGLT2 inhibitor luseogliflozin

Jinnouchi, H., Yoshida, A., Tsuyuno, H., Iwamoto, K., Sugiyama, S., Hieshima, K., Kajiwara, K., Kurinami, N., Suzuki, T., Jinnouchi, K., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108916 · Cited by 4 · see citing works

SGLT2 Inhibitors in Long COVID Syndrome: Is There a Potential Role?

Zimmermann, P., Sourij, H., Aberer, F., RILSTONE, S. K., Schierbauer, J., & Moser, O. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10120478 · Cited by 4 · see citing works

Drug Safety Evaluation of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Comorbid Patients by Review of Systemic Extraglycemic Effects

Omari, M. B., Naseri, S., & Hassan, A. J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s448670 · Cited by 3 · see citing works

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

Xu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Mayoux, E., Kaneko, S., & Ota, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.028 · Cited by 497 · see citing works

GLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.

Liang, X., Naoto, N., Nagashimada, M., Zhuge, F., Yinhua, N., Chen, G., Mayoux, E., Kaneko, S., & Tsuguhito, O. (2017) · Kanazawa University Repository for Academic Resources (DSpace) (Kanazawa University)

SGLT2 inhibition by empagliflozin promotes fat browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice

冠良, 陳. (2018) · The Japan Endocrine Society

Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet

Xu, L., Nagata, N., Chen, G., Nagashimada, M., Zhuge, F., Ni, Y., Sakai, Y., Kaneko, S., & Ota, T. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000783 · Cited by 109 · see citing works

SGLT2 inhibitors modulate inflammation by altering macrophage metabolism and decreasing monocyte platelet aggregates 3256

Safa, B. I., Oakes, J. M., Simmons, J. D., Kirk, L. A., Olson, E., Bailin, S. S., Gabriel, C. L., Luther, J. M., Koethe, J. R., Kalams, S. A., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf283.1074